In the SHINE trial, enteropathy biomarkers changed significantly between the 1- and 18-month visits (23); stool MPO and neopterin tended to be lower at 18 months, indicative of reduced innate immune cell accumulation in the lamina propria in older children. The gene discussed is MPO; the disease is Abnormal intestine morphology.